Price Samantha L, Bloom Stephen R
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, UK.
Front Horm Res. 2014;42:147-54. doi: 10.1159/000358343. Epub 2014 Apr 7.
The hormone PYY is released from the distal gut in response to nutrient ingestion. Numerous studies have shown that PYY3-36, the most abundant circulating isoform of PYY, reduces food intake when given to obese rodents and humans. Its infusion to mimic postprandial levels in fasting subjects inhibits appetite, suggesting a physiological role in postprandial satiety. However, the mechanisms underlying this effect remain unclear. Neuronal activity within several brain areas appears to be modified following peripheral administration of PYY3-36 and a direct effect on the central nervous system is possible. Several studies suggest that PYY3-36 levels are reduced in obesity and are elevated following gastric bypass surgery, possibly contributing to the increased feelings of satiety following this procedure. Whether PYY has a role in the regulation of energy expenditure is currently unclear. However, due to the clear appetite-inhibitory effect of PYY, this hormone continues to be investigated as a potential therapeutic agent in the treatment of obesity.
激素PYY在摄入营养物质后从肠道远端释放。大量研究表明,PYY最丰富的循环异构体PYY3-36,给予肥胖啮齿动物和人类时可减少食物摄入量。在禁食受试者中输注PYY3-36以模拟餐后水平可抑制食欲,提示其在餐后饱腹感中具有生理作用。然而,这种作用的潜在机制仍不清楚。外周给予PYY3-36后,几个脑区的神经元活动似乎发生了改变,并且对中枢神经系统可能有直接作用。几项研究表明,肥胖者体内PYY3-36水平降低,胃旁路手术后升高,这可能是该手术后饱腹感增加的原因。目前尚不清楚PYY是否在能量消耗调节中起作用。然而,由于PYY具有明确的食欲抑制作用,这种激素仍作为治疗肥胖的潜在治疗药物继续被研究。